Mr Shri Jagat Prakash Nadda  
Union Minister  
Ministry of Health & Family Welfare  
155 - A, Nirman Bhavan  
New Delhi - 110108  
India  

17 November 2017

Dear Minister,

Re: Approval of Measles Rubella Vaccine Campaign for India

We are writing in response to the request of Government of India to Gavi, the Vaccine Alliance, for technical assistance support from WHO-NPSP and UNICEF for the Measles Rubella Vaccine (MR) campaign, as per the letters dated 24 May 2017 and 19 September 2017.

We are pleased to inform you that this support has been approved by Gavi and share with you a revised Decision Letter to confirm the support. This revised Decision Letter replaces the letter of 28 November 2016 and states, additionally, that Gavi has approved $7 million for 2018 from the requested $8.5 million, categorised under MR operational support.

As per Gavi rules, the remaining $1.5 million for 2019, was committed and will be approved in 2018 subject to satisfactory performance of the programme and resource availability.

This funding is reallocated from the Rotavirus vaccine support that is part of the $500 million allocation as provided under Annex 6 of the Partnership Framework Agreement (PFA). This reallocation is made firstly on the basis that there may be savings from the ongoing Rotavirus vaccine tender and secondly, on the basis that the Government of India will meet any shortfall in funding for Phase 3 of the Rotavirus vaccine introduction from domestic funding, as set out in the letter to Gavi dated 24 May 2017.

The programme budget for vaccine doses remains unchanged. As stated in the previous Decision Letter, the programme budget includes donated doses, in addition to the Gavi commitment of US$115 million for MR support. In calculating the doses available to India, Gavi used the 2016 price for the MR vaccine, which included taxes levied on the vaccine. Any changes in the MR vaccine price will be reflected in subsequent revisions of the Decision Letter.

Finally, we note that the Gavi Board’s decision to provide catalytic support for India’s MR programme is subject to the provisions of Annex 6 of the PFA, in particular the commitments of the Government of India to fund additional costs required as well as scale-up of the
programme, and to implement the programme as set out in the approved Performance Framework.

Please do not hesitate to contact the Senior Country Manager for India, Carol Szeto (cszeto@gavi.org), if you have any questions or concerns.

We remain at your disposal for any further enquiry.

Yours sincerely,

[Signature]

Hind Hatib-Othman
Managing Director, Country Programmes

Cc:
PS, The Minister of Health and Family Welfare
PS, The Minister of Finance
Secretary, Ministry of Health and Family Welfare
Additional Secretary, MD NHM, Ministry of Health and Family Welfare
Joint Secretary, Ministry of Health and Family Welfare
Deputy Commissioner (Immunization); MoHFW
Deputy Commissioner (UIP), MoHFW
WHO Country Representative
UNICEF Country Representative
WHO HQ
UNICEF Programme Division
UNICEF Supply Division

GAVI Alliance
2 Chemin des Mines
1202 Geneva, Switzerland
Tel. + 41 22 909 65 00
Fax + 41 22 909 65 50
www.gavi.org
info@gavi.org
India Support for
Measles Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme

1. Country: India

2. Grant number: 17-IND-18a-X / 1819-IND-20a-Y

3. Date of Decision Letter: 17 November 2017 (this letter replaces the Decision Letter dated 28 November 2016)

4. Date of the Partnership Framework Agreement: 12 June 2015

5. Programme title: NVS, Measles Rubella Campaign

6. Vaccine type: Measles Rubella

7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED

8. Programme duration¹: 2017

9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)

<table>
<thead>
<tr>
<th>Programme Budget Gavi (US$)</th>
<th>2017</th>
<th>Total²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programme Budget Gavi</td>
<td>US$115,000,000</td>
<td>US$115,000,000</td>
</tr>
<tr>
<td>Programme Budget Gavi - &quot;Donated Doses&quot; (US$)</td>
<td>US$12,341,015</td>
<td>US$12,341,015</td>
</tr>
<tr>
<td>Programme Budget Gavi - TOTAL</td>
<td>US$127,341,015</td>
<td>US$127,341,015</td>
</tr>
</tbody>
</table>

10. Vaccine introduction grant (in US$): Not applicable

11. Indicative annual amounts: (subject to the terms of the Partnership Framework Agreement)³

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2017 - Gavi</th>
<th>2017- Gavi &quot;Donated Doses&quot;</th>
<th>2017- Gavi TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Measles Rubella vaccines doses</td>
<td>176,923,100</td>
<td>20,000,000</td>
<td>196,923,100</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>US$115,000,000</td>
<td>US$12,341,015</td>
<td>US$127,341,015</td>
</tr>
</tbody>
</table>

¹ This is the entire duration of the Programme
² This is the total amount endorsed by Gavi for the entire duration of the Programme. The Programme budget comprises $115 million as committed to India as part of the India Partnership Strategy (adjusted for budget variance) and $12 million under the donation agreement with the manufacturer. This is based on the current price of the vaccine, as well as taxes and freight costs.
³ This is the amount that Gavi has approved.
12. Procurement agency: UNICEF

13. Self-procurement: Not applicable

14. Co-financing obligations: Not applicable

15. Operational support for campaigns:

<table>
<thead>
<tr>
<th>Grant amount (US$)</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>US$7,032,885</td>
<td>US$1,475,135*</td>
</tr>
</tbody>
</table>

*amount subject to Gavi approval in 2018

16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:

<table>
<thead>
<tr>
<th>Reports and other information</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIA technical report</td>
<td>Within three months of the finalisation of the campaign</td>
</tr>
<tr>
<td>Post campaign coverage survey report and actual expenditures report</td>
<td>As soon as available</td>
</tr>
<tr>
<td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance</td>
<td>To be agreed with Secretariat</td>
</tr>
</tbody>
</table>

17. Financial clarifications: Not applicable

18. Other conditions: Gavi’s catalytic support for India is subject to the provisions in Annex 6 of the Partnership Framework Agreement, and in particular:

- The commitments of the Government of India to provide financing to fund the additional costs required for each programme that is funded with the Partnership Support and to scale up the programmes; and
- Implementation of the programmes in line with the timelines, milestones and indicators set out in the performance framework.

Signed by,

Hind Khatib-Othman
Managing Director, Country Programmes
17 November 2017

---

UNICEF will not be requested to facilitate the delivery of any “Donated doses”. 

GAVI Alliance
2 Chemin des Mines
1202 Geneva, Switzerland

Tel. +41 22 909 65 00
Fax +41 22 909 65 50
www.gavi.org
info@gavi.org